Amgen files calcitonin NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen submits its first-in-class oral calcimimetic agent, cinacalcet, for the treatment of secondary hyperparathyroidism associated with chronic kidney disease, the firm announces Sept. 8. Cinacalcet modulates the calcium-sensing receptor on the parathyroid gland. The NDA is "based upon the successful completion of Phase III studies"; data will be presented at the American Society of Nephrology annual meeting in November. Cinacalcet is the first small-molecule therapeutic for the biotech firm...
You may also be interested in...
Amgen Highlighting Cinacalcet Ability To Meet New Targets In Guidelines
Amgen’s pre-approval positioning for cinacalcet is focusing on the calcimimetic’s ability to meet the lower target mineral levels set in the National Kidney Foundation’s new guidelines for bone metabolism and disease.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.